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ABSTRACT The sophorolipid class of biosurfactants is ﬁnding increasing use in per-
sonal care as well as pharmaceutical products and has the potential to disrupt bio-
ﬁlm formation and inhibit the growth of a variety of clinically relevant organisms. In
order to investigate potential biomedical applications of sophorolipids derived from
nonpathogenic organisms, we fractionated and puriﬁed glycolipid biosurfactant
sophorolipids produced by the yeast Starmerella bombicola, which yielded both
acetylated and nonacetylated acidic C18:1 congeners that were essentially free
from other contaminants (95% purity). These acidic sophorolipids have antimi-
crobial activities against the nosocomial infective agents Enterococcus faecalis
and Pseudomonas aeruginosa, with signiﬁcant reductions in CFU at concentra-
tions of as low as 5 mg ml1. In addition, the sophorolipid showed similar ef-
fects against the same two bacterial strains when combined with kanamycin or
cefotaxime. As a potential use of these sophorolipids is as a component of topi-
cally applied creams for the treatment of wound infections, it is clear that they
must have no demonstrable adverse effect on wound healing. To assess this, we
evaluated mammalian cell toxicity in vitro using viability tests, which revealed no
adverse effect on either endothelial or keratinocyte-derived cell lines with so-
phorolipid concentrations of  0.5 mg ml1. In addition, in vivo experiments using
a mouse skin wounding assay revealed that the time course of healing wounds was
unaffected by the application of sophorolipid-containing creams, and histological ex-
amination of regenerated skin tissue conﬁrmed that the healing process was similar
to that observed for control animals, with no evidence of inﬂammation. These re-
sults are consistent with the suggestion that acidic sophorolipids can be used as a
component of antimicrobial creams to reduce the risk of wound infection during
healing.
KEYWORDS acidic sophorolipids, microbial pathogens, growth inhibition,
endothelium, keratinocytes, in vivo, wound healing, Enterococcus, Pseudomonas
aeruginosa, adjuvants, antimicrobial activity
Microbial contamination is a major obstacle to tissue healing, with cutaneouswounds in particular representing one of the major routes of exposure to
pathogenic bacterial strains. A systematic review (1) recently identiﬁed Pseudomonas
aeruginosa as the most commonly reported burn-wound-infective pathogen. Multiple
strains of multidrug-resistant P. aeruginosa have been isolated from burn patients in
India (2), and enterococcal in addition to pseudomonad species have been identiﬁed in
cases of diabetic foot ulcer infections (3). Many medical and surgical procedures carry
a signiﬁcant risk of microbial infection (4, 5), with a signiﬁcant proportion of these cases
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demonstrating bacterial drug resistance, making the search for alternative approaches
to treatment a clinical imperative.
Surfactants are a diverse group of amphiphilic compounds commonly used in
detergents and products for human consumption or application (such as the food
industry or in cosmetic or medical creams, for example), although their production is
heavily reliant on the petrochemical industry and associated raw materials. In contrast,
biosurfactants are a diverse group of surfactants produced by certain species of yeast
or bacteria, which represent a more sustainable and perceived environmentally friendly
alternative to traditional surfactants. There is increasing evidence that microbial bio-
surfactants, as well as possessing industrially valuable properties of detergency, emul-
siﬁcation, and foaming, also have signiﬁcant bioactivities, including inhibitory or anti-
bacterial adjuvant activities against various microorganisms (6–18) and speciﬁc
anticancer activity (19).
Sophorolipids (SLs) are a diverse group of glycolipid biosurfactants, characterized by
a sophorose molecule attached to a variable-length fatty acid chain, that can be
produced in signiﬁcant quantities by the yeast Starmerella bombicola. The sophorose
molecule may be acetylated in two positions, the carbon chain between 16 and 18
atoms in length, and contain no, one, or more double bonds. The arrangement of the
fatty acid chain accounts for the two major SL subtypes: acidic SLs terminate in a
carboxylic acid group (open chain), while the chain in the lactonic type is reattached to
the sophorose molecule, forming a closed-ring structure. The antimicrobial effects of
SLs are dependent on the SL structure and class of bacteria examined, yet SLs are
predominantly produced and used as mixtures, with very few studies examining the
effects of SL samples containing well-deﬁned and puriﬁed single congeners. In addi-
tion, sophorolipids have virucidal and antibiotic adjuvant characteristics (6, 7) and may
have potential applications in infection, wound healing, or anti-inﬂammatory contexts
(8, 19). However, the widely variable methods of production, extraction, and puriﬁca-
tion, coupled with the diversity of possible SL structures and a lack of sufﬁcient
characterization of preparations, make comparison between data from in vitro and in
vivo studies difﬁcult to interpret.
The purpose of our studies was to use a highly puriﬁed preparation of acidic
sophorolipid that contained only the C18 congener (predominantly nonacetylated) and
ascertain if it could act as an antimicrobial agent or antibiotic adjuvant against two
common nosocomial infection-causing bacteria: Enterococcus faecalis and Pseudomonas
aeruginosa. Furthermore, we also explored whether these acidic sophorolipids inhibited
the growth of mammalian cells (endothelium, ﬁbroblasts, and keratinocytes) that are
relevant to the wound healing process in vitro and are compatible with the healing of
uncomplicated wounds in vivo.
RESULTS
Analysis of bacterial growth with puriﬁed nonacetylated acidic sophorolipid
treatment. Following treatment with doses of acidic sophorolipids of 5 mg ml1, a
clear inhibitory effect on the growth of Enterococcus faecalis was observed: colony
formation was zero with 20 mg ml1 C18:1 NASL in two out of three experiments (Fig.
1A). Inhibition of growth of Pseudomonas aeruginosa was also evident at concentrations
of 5 mg ml1 acidic sophorolipid; following treatment with 20 mg ml1 C18:1 NASL,
colony formation was zero in one out of three experiments (Fig. 1B).
Antibiotic adjuvant activity of sophorolipid. In culture experiments, solutions of
10 and 20 mg ml1 of C18:1 NASL successfully inhibited the growth of both bacterial
species (as determined by optical density at 600 nm [OD600] measurements); therefore,
for the adjuvant assay, we tested subinhibitory concentrations of 2 and 4 mg ml1,
respectively.
The addition of puriﬁed C18:1 NASL to bacterial cultures reduced the MIC of
kanamycin and cefotaxime in the majority of replicates; however, the value of the MIC
itself was difﬁcult to determine due to interexperimental variation (Table 1). The highest
concentration of C18:1 NASL was clearly the most effective at reducing antibiotic MICs
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for both strains and both drugs. In fact, 4 mg ml1 C18:1 NASL alone effectively reduced
the growth of Pseudomonas aeruginosa. The adjuvant effect was most obvious for
strains treated with 4 mg ml1 C18:1 NASL together with cefotaxime. The effect of the
addition of C18:1 NASL on the kanamycin MIC was generally less marked than that on
cefotaxime. Interestingly, the MIC of kanamycin against Pseudomonas aeruginosa was
increased with the addition of 2 mg ml1 C18:1 NASL.
In vitro cell viability assay. The addition of acidic C18:1 NASL to culture media in
doses ranging from 0.01 to 500 g ml1 did not affect the cell viability of human
umbilical vein endothelial cells (HUVECs), human dermal microvascular endothelial cells
(HDMVECs), or HaCaT cells (Fig. 2), as measured by an MTT [3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium] bromide assay.
In vivo wound healing assay. All wounds were completely closed, with no remain-
ing residual coagulum covering, by day 16 of the study. Treatment with cream
containing C18:1 acidic sophorolipid did not signiﬁcantly affect wound size on the
monitored days in comparison to the control group (Fig. 3; see also the supplemental
material). The wound size for the vehicle group was initially larger than that for controls
on day 4 (P  0.05) but was smaller than that for controls by day 8 of the study (P 
0.001) (see the supplemental material).
Histology of healing wounds. Qualitative assessment of light microscopic images
from samples taken 21 days after injury revealed typical morphological features of
murine skin samples, including a thin corniﬁed epithelial layer, a dermal layer with
numerous obliquely sectioned hair follicles, and a deep 3- to 5-cell-layer-thick pannic-
ulus carnosus (skeletal muscle) layer (see Fig. S2 in the supplemental material). Mor-
phological features of tissue structure were consistent across all treatment groups, with
no evidence of ﬁbrosis or lymphocytic inﬁltration being noted.
FIG 1 Growth (CFU per milliliter) of Enterococcus faecalis (A) and Pseudomonas aeruginosa (B) was
signiﬁcantly reduced by exposure to 0.5 to 2% puriﬁed acidic sophorolipid (C18:1 NASL). Representative
data from one of three experiments are presented (means  standard deviations; n  4 technical
replicates; ****, P  0.0001).
TABLE 1MICs and MECs of kanamycin or cefotaxime against Enterococcus faecalis or
Pseudomonas aeruginosa, alone or in combination with puriﬁed C18:1 NASL
Treatment MIC (mg/liter) MEC (mg/liter)
Enterococcus faecalis
Kanamycin 4–16 2–4
2 mg ml1 C18:1 NASL 2 2–4
4 mg ml1 C18:1 NASL 2–4 Not determined
Cefotaxime 0.5–2 0.5–2
2 mg ml1 C18:1 NASL 0.5–1 0.25–1
4 mg ml1 C18:1 NASL 0.016–1 0.062–1
Pseudomonas aeruginosa
Kanamycin 8 8
2 mg ml1 C18:1 NASL 8–16 8
4 mg ml1 C18:1 NASL 0.25 0.25
Cefotaxime 0.5–4 0.5–4
2 mg ml1 C18:1 NASL 0.5 0.62
4 mg ml1 C18:1 NASL 0.062 0.062
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DISCUSSION
To our knowledge, the work presented here details the ﬁrst investigation of the
application of puriﬁed sophorolipids in the context of healing wounds. In addition to
our observations of consistent antimicrobial and antibiotic adjuvant activities of this
FIG 2 Reduction of formazide salt (absorbance at 570 nm) (means  standard deviations; n  6) to
formazan crystals in HUVECs (A), HDMVECs (B), and HaCaT cells (C) in vitro is not affected by the addition
of acidic C18:1 SL. A low serum concentration (2%) served as the control conditions for endothelial cells
(A and B), and a high serum concentration (10%) served as the control conditions for HaCaT cells (C).
Representative data from two repeat assays are shown.
FIG 3 Sizes of wounds (square millimeters; means  standard deviations; n  8) 8 days after an excision
was created on depilated dorsal skin of male C57BL/6J mice and treated with aqueous cream with PBS
(vehicle; n  8) or various doses of puriﬁed C18:1 NASL in aqueous cream for 7 days or left untreated
(control). Asterisks indicate a signiﬁcant difference in wound sizes between a test group and the control
group (*, P  0.05; ***, P  0.001).
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puriﬁed sophorolipid product, we show that C18:1 NASL does not affect cell viability in
human endothelial cells (HUVECs and HDMVECs) and keratinocytes (HaCaT cells) in vitro
or the rate of wound healing in a murine model of longitudinal wound healing in vivo.
Taken together, these data provide evidence that puriﬁed sophorolipid application is
compatible with healing wounds and could be beneﬁcial in the context of wound
contamination or infection with opportunistic bacterial pathogens.
In terms of the effects of sophorolipids on cultured cells, much of the reported data
focuses on relatively impure preparations, and these studies were primarily directed at
antimigratory or cytotoxic effects on phenotypically invasive cell lines in the context of
anticancer therapy (9–14) rather than compatibility with and low toxicity to normal
(nontransformed) cells. Our observations are consistent with the suggestion of con-
tinuing research into possible therapeutic applications. More detailed investigations of
the interactions between sophorolipids and cultured human cells, such as assays of
membrane integrity, biomarkers of irritancy, or inﬂammation, for example, will be vital
to inform the progression of these agents into clinical application.
A range of sophorolipid preparations, including mixtures containing both acidic and
lactonic structures, were shown to be ineffective against Gram-positive and Gram-
negative bacteria (Escherichia coli and Staphylococcus aureus), with MICs above 512 g
ml1, similar to the sophorolipid concentrations used to demonstrate adjuvant activity
in our study (15). However, when ethanol was employed as a vehicle, inhibition of E. coli
and S. aureus was observed at concentrations of 128 g ml1. A “natural SL” mixture
(approximately 75% lactonic and 25% acidic structures) was effective against E. coli at
1 mg ml1 and against S. aureus at 15 to 150 g ml1 (6), concentrations approximately
5- to 10-fold lower than the concentrations applied in our antimicrobial studies. The
mixture previously reported (6) also displayed adjuvant activity at lower concentra-
tions,1 mg ml1, than those that we have reported here. Another study of natural SL
mixtures with a variety of sugar head groups reported antimicrobial activity against a
range of bacteria, which were predominantly Gram positive (16) and evident at 100- to
1,000-fold-lower concentrations than the ones that we tested. These differences in
antimicrobial activities may be associated with the presence of lactonic structures in
natural SL mixtures. The range of activities presented by sophorolipid structures is
further highlighted by the observation that acidic SL structures are virucidal against HIV
in vitro at doses of 3 mg ml1 (7), similar to the doses that we observed to exert an
adjuvant effect on bacterial pathogenic strains. The dosages employed during our in
vitro antimicrobial studies that were effective in bacterial killing are consistent with
those that were administered intravenously in vivo (1- to 1.2-mg dose of a natural SL
mixture) and were subsequently shown to prevent lethal septic shock in two distinct rat
models of peritonitis (8, 19).
While research activity in the ﬁelds of antimicrobial, antiviral, antiadhesion, or
adjuvant activities of various types of biosurfactants is increasing, their applications in
the context of wound healing are rare. The dirhamnolipid (“BAC-3”) produced by
Pseudomonas aeruginosa is well tolerated and promoted faster healing in studies
examining burn wounds in mice and rats; these studies led to its successful application
in a single clinical case of chronic decubitus ulcer (17, 18). However, differences in
wound types, wound sizes, animal models, surfactant types, and biosurfactant mixtures
make comparisons between these studies difﬁcult. In order to improve our understand-
ing of the potential beneﬁts or risks of this diverse group of compounds in wound
healing, information on the composition of biosurfactant mixtures and standardization
of the experimental wound healing model that is employed will be crucial.
In comparison to the control group, only the addition of cream that contained the
vehicle-only solution resulted in a signiﬁcant change in wound size, with no histological
differences being detected between treatment groups. We interpreted these results to
indicate that topical creams containing C18:1 NASL play a passive role in the process of
healing uncomplicated, noninfected wounds. Factors affecting the percutaneous pen-
etration of sophorolipids, such as molecular weight and lipophilicity, may be important
for choosing an appropriate delivery mechanism or vehicle. Investigating the roles of
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acidic sophorolipid preparations in critical micelle concentrations and characteristics of
dissociation from suitable creams or their extent of percutaneous penetration may thus
be beneﬁcial to determine their efﬁcacy for antibiotic prophylaxis of wounded skin.
While the majority of studies report that the lactonic sophorolipids are more
effective in terms of antimicrobial effects or adjuvant activity, the C18:1 NASL sample
tested was selected for evaluation in cultured cells in vitro and in vivo because of its
purity (veriﬁed at the source by nuclear magnetic resonance [NMR]) and lyophilized
state. The relative solubility of our NASL stock solutions varied according to the vehicle
used in each assay. In this study, we used the highest ﬁnal concentrations possible in
both microbiological assays (4 mg/ml in phosphate-buffered saline [PBS]) and mam-
malian cell culture assays (0.5 mg/ml [500 mg/ml] in culture medium). We were unable
to achieve higher doses in either of these cases, as they led to precipitation in the
growth medium and thus an inability to calculate accurate ﬁnal concentrations. This is
not ideal, as there is no overlap in dosages between the antimicrobial effect that we
observed (maximal at 4 mg/ml) and the highest dose used for cell toxicity testing (0.5
mg/ml). However, we believe that observations of full-thickness skin healing in vivo
following the topical application of high dosages (200 and 400 mg/kg of body weight,
well above the equivalent dose in tissue culture) are consistent with a lack of toxicity
of puriﬁed NASL.
Furthermore, the in vitro cytotoxic effects of puriﬁed lactonic sophorolipids ob-
served by our group (20) extended to control cell lines as well as cancer cell lines; this
was not the case for similarly tested puriﬁed acidic sophorolipid. Overall, we conclude
that the topical application of puriﬁed acidic sophorolipid did not impair wound
healing in vivo, which, together with evidence of antibacterial, antibioﬁlm, and antibi-
otic adjuvant activity, supports the future evaluation of sophorolipids as novel wound
healing agents, particularly in the contexts of acutely or chronically infected wounds.
MATERIALS AND METHODS
Sophorolipids. A puriﬁed acidic sophorolipid sample was produced from the yeast Starmerella
bombicola by using the culture and puriﬁcation methods outlined previously by Van Bogaert et al. (21)
and comprised 90% nonacetylated C18:1 acidic sophorolipid (C18:1 NASL) as determined by NMR
spectroscopy (at the point of puriﬁcation). Other congeners present include a mixture of sophorolipid
structures with chain lengths of C16 to C18 containing 0 to 2 double bonds. Sophorolipid solutions of
various concentrations (by mass) were prepared in the relevant culture media for in vitro experiments or
sterile PBS for in vivo studies.
Analysis of bacterial growth with puriﬁed nonacetylated acidic sophorolipid treatment. En-
terococcus faecalis (ATCC 29212) and Pseudomonas aeruginosa (PAO1) were obtained from Ulster
University Microbiology Research Group stock. Nutrient broth (5 ml; Oxoid, Basingstoke, UK) was
inoculated with a single colony and then transferred to a shaking incubator overnight (16 to 18 h). Each
culture grown overnight was adjusted, under sterile conditions, to an OD600 of 0.05 (1 	 108 CFU/ml)
and then diluted further into broth containing sophorolipid (20 mg ml1 C18:1 NASL), such that the ﬁnal
concentration of the culture was 1/100 of the inoculum adjusted to an OD of 0.05. Inoculated broth (100
l) with or without C18:1 NASL was loaded, alongside blank controls, into 96-well microtiter plates (Nunc;
Thermo Fisher, UK), which were incubated at 37°C for 12 h with no agitation. Cultures were then
appropriately diluted, spread onto nutrient agar plates (Oxoid), and incubated at 37°C. Following 12 h of
incubation, agar plates were photographed for colony counting by using ImageJ software (v1.50b; NIH).
The above-described procedure was performed three times in total for each strain, starting with cultures
of separate colonies grown overnight.
Antibiotic adjuvant activity of sophorolipid. Antibiotics (cefotaxime and kanamycin) were pur-
chased from Sigma (Dorset, UK). Stock antibiotic solutions were prepared in sterile water and ﬁlter
sterilized as required. Appropriate dilutions of antibiotic (512 mg/liter) were prepared in sterile nutrient
broth (Oxoid, Basingstoke, UK) before being loaded (100 l) into separate columns of a 96-well plate.
Each plate contained a 2-fold dilution series of antibiotic (n  8 per concentration). Puriﬁed acidic SL
solutions were prepared in nutrient broth. Diluted sophorolipid samples and loaded microtiter plates
were stored at 4°C and used within 5 days of preparation.
Initial bacterial cultures were prepared by inoculating 5 ml nutrient broth with a single colony from
an agar plate. The inoculum was placed into a shaking incubator (37°C) for 6 to 8 h and then adjusted
to an optical density (at 600 nm) of 0.05. Cultures were then diluted (1/50) into nutrient broth alone
(control) or into nutrient broth containing puriﬁed acidic SL (4 or 8 mg ml1 C18:1 NASL). The control
inoculum was dispensed (100 l) into one half of the plate (antibiotic plus culture only; n  4 wells), and
the SL-containing inoculum was dispensed (100 l) into the other half of the plate (antibiotic plus culture
plus SL at 2 or 4 mg ml1; n  4 wells). Nutrient broth containing the appropriate concentration of
sophorolipid or no SL was included as a control (n  4 wells). The plates were sealed with Paraﬁlm and
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incubated in a shaking incubator at 37°C for 12 h, at which point the optical density (at 600 nm) was
recorded and the plates were visually inspected for growth, indicated by opacity. Each experiment was
performed three times.
Data and statistical analysis. Statistical analyses were performed by using GraphPad Prism (v6.01).
Data sets were analyzed by comparing the mean endpoint for each test group to that for the relevant
control group by one-way analysis of variance (ANOVA) with Holm-Sidak’s multiple-comparison tests.
Any value differing by more than 0.2 OD units from at least 2 other values in the group were omitted
from analysis for all assays. This step was informed by previous experience whereby air bubbles,
excessive precipitation, or contamination was linked to intragroup variation of this magnitude, up to the
detection limits of the equipment (approximately 1 OD unit). This approach was not applied where mean
values were above 1 OD unit, which was classed as “positive.”
The highest concentration of puriﬁed acidic sophorolipid applied in the adjuvant assay (4 mg ml1)
invariably increased the optical density of broth (indicated visually and by Mann-Whitney comparisons
of OD measurements); therefore, raw OD data were adjusted by taking into account the background
from the relevant SL-positive or SL-negative control. To determine the adjuvant efﬁcacy of puriﬁed C18:1
NASL, the MIC of the antibiotic was deﬁned as the lowest concentration at which the OD600 was not
signiﬁcantly different between culture and antibiotic conditions and the relevant blank control, and the
minimal effective concentration (MEC) was deﬁned as the lowest concentration of antibiotic at which the
OD600 was signiﬁcantly lower than that of the relevant culture control.
Tissue culture. HDMVECs and HUVECs (Caltag Medsystems, Cambridgeshire, UK) were cultured in
M200 phenol red-free (PRF) culture medium supplemented with low-serum growth supplement (LSGS)
(giving a ﬁnal serum concentration of 2%; Gibco, UK). Human keratinocytes (HaCaT cells) were cultured
in high-glucose Dulbecco’s modiﬁed Eagle’s medium (DMEM) (4.5 g liter1 glucose) supplemented with
10% fetal bovine serum (FBS; Gibco, UK).
In vitro cell viability assay. Cells were trypsinized as normal, counted by using trypan blue, and
dispensed at various concentrations into 96-well plates. HaCaT cells were washed with PBS after adhering
to plates and incubated overnight (16 to 18 h) in serum-free medium, whereas endothelial cells remained
in LSGS-supplemented medium. The medium was then removed, and the wells were washed once more
in PBS before the application of fresh complete medium containing puriﬁed acidic sophorolipid (0.01 to
500 g ml1) or etoposide (5 M) or of medium with a low (2%) or high (10%) fetal calf serum content.
Plates were subsequently incubated for 22 h, after which MTT was added (under low-light conditions) to
a ﬁnal concentration of 0.5 mg ml1, and the plates were incubated for a further 4 h. Media were then
removed, and dimethyl sulfoxide (DMSO) (200 l) was dispensed into each test well with gentle mixing
before the optical density at 570 nm was recorded.
Animals and surgical procedures. Adult (8- to 14-week-old) male C57BL/6J mice were obtained
from Harlan UK. Animals were housed singly with freely available food and water and provided with soft
adsorbent pads as bedding for at least 1 week prior to surgery, with their body weights being measured
during this time. In order to reduce the risk of infection associated with contaminated bedding and to
reduce stress, animals were placed into fresh cages the day before surgery, and a clean bedding pad was
placed on top of the previous pad on the day of the experiment.
Mice were anesthetized by intraperitoneal injection with ketamine and xylazine (100 mg kg1 and 10
mg kg1, respectively) and provided with subcutaneously administered preemptive pain relief (2 mg
kg1 meloxicam [Metacam]). Following appropriate anesthesia, the dorsal surface was shaved with
electric clippers, and hair was removed by the application of a commercially available depilatory cream.
The skin was prepared for surgery by wiping with three repeat applications of gauze soaked in warmed
Hibiscrub followed by warmed 70% IMS. Animals were then placed onto a warming mat for the duration
of the surgical procedure.
Circular dressings, 2 cm in diameter, were cut from sheets of Opsite Flexigrid transparent adhesive
dressings (Smith & Nephew, Hull, UK). The mouse was placed in ventral recumbency, and the dressings
were then placed onto the depilated dorsal skin, centrally across the midline and between the forelimbs,
and allowed to adhere for a few moments. The mouse was then placed into ﬂank recumbency, and the
dressing was used to create a fold of the dorsal skin surface. A uniform, circular wound was created by
using an 8-mm dermal biopsy punch, by applying half the blade of the punch to the folded skin (Fig. 1A)
while the dressing remained in place. Animals were placed into a warming cabinet, with moistened food
in the cage, until they recovered from anesthesia.
Treatment and monitoring. Mice were assigned to a treatment group of 20, 200, or 400 mg kg1
sophorolipid or a control group (n  8 per group). Sophorolipid was prepared in PBS and then mixed
with commercially available aqueous cream in a 1:1 (vol/wt) ratio. The control group was treated with an
aqueous cream similarly mixed with an equal volume of PBS. Animals were brieﬂy anesthetized with
isoﬂurane to permit the administration of treatment and consecutive photographs to be made of the
wounds. Treatment was applied daily to the surface of the wounds for 7 days (Fig. 1B), with photographs
being taken on day 1 (day of surgery), day 2, and then every 2 days thereafter. The plunger of a 1-ml
syringe was used to smooth the edges of the cream around the wound edge if necessary. The dressing,
if not detached already, was removed on day 3 postsurgery. Intake of food and water was recorded
periodically throughout the study. On day 21, animals were euthanized in a CO2 atmosphere, and the
skin surrounding the wound area was collected, laid ﬂat onto moistened ﬁlter paper, and placed ﬂat into
10% neutral buffered formalin. Following ﬁxation at 4°C, skin samples were processed by using an
autoprocessor, embedded in parafﬁn blocks, sectioned at 5 m, and stained with hematoxylin and eosin
according to conventional protocols.
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Image and statistical analysis. Statistical analyses for all assays were performed with the aid of
GraphPad Prism (v6.01). Wound size in the in vitro and in vivo assays was measured by using ImageJ
software (22). In vitro data sets were analyzed by comparing the mean endpoint for each test group to
that for the control group by a Kruskal-Wallis test with Dunn’s multiple-comparison test. For in vivo
assays, mean wound sizes on each monitoring day were compared between each treatment group and
the control group as described above.
All relevant international, national, and/or institutional guidelines for the care and use of animals
were followed. Speciﬁcally, approval from the local (Ulster University) ethics committee was granted, and
experiments were conducted according to the guidelines provided by the UK Animals (Scientiﬁc
Procedures) Act 1986 and according to appropriate national ethical approval from the UK Home Ofﬁce.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
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